AbbVie Bears Load Up on December 2027 Puts as Stock Slides Near 52-Week High
By TrendSpider Editor
AbbVie Inc. (ABBV) is drawing attention in the options market today after two notable put contracts totaling $2,866,500 in combined premium hit the tape, both targeting a $260 strike expiring December 17, 2027. The activity arrives as shares trade at $287.02, down 1.99% on the session, and comes aga
AbbVie Bears Load Up on December 2027 Puts as Stock Slides Near 52-Week High
AbbVie Inc. (ABBV) is drawing attention in the options market today after two notable put contracts totaling $2,866,500 in combined premium hit the tape, both targeting a $260 strike expiring December 17, 2027. The activity arrives as shares trade at $287.02, down 1.99% on the session, and comes against a broad 52-week range of $191.00 to $302.93, placing the stock closer to its annual highs than its lows. The size and open interest ratios on these contracts suggest this is far from routine hedging.
Key Drivers of the ABBV Stock Move
- Main Catalyst: Two put contracts on ABBV landed Wednesday, both at the $260 strike expiring December 17, 2027. The first carried a size of 1,200 contracts with an open interest ratio of 8,000% and a premium of $2,293,200. The second added 300 contracts at a 2,000% OI ratio for an additional $573,300 in premium. The outsized OI percentages indicate that volume on these contracts dwarfs any existing open interest, flagging this as fresh, conviction-driven positioning.
- Bull Case: Both contracts are out of the money, with the $260 strike sitting roughly $27 below the current price of $287.02. If ABBV holds near its current level or continues trending toward its 52-week high of $302.93, these puts expire worthless and the bearish thesis fails. The stock has already recovered significantly from its 52-week low of $191.00, reflecting strong underlying momentum.
- Bear Case: A combined $2,866,500 in put premium with expirations stretching to December 2027 signals that at least one large participant is positioning for a meaningful drawdown over the next 13 months. A move to $260 would represent a decline of roughly 9% from current levels, and the 8,000% open interest ratio on the larger contract is an unusually aggressive signal that deserves attention.
The forward setup for ABBV is a tug of war between a stock trading near multi-year highs and what appears to be a well-funded bearish bet on a longer-term pullback. The 13-month expiration on these puts is notable. Rather than a short-term tactical trade, this positioning suggests the trader is expressing a view that extends well into 2027, potentially tied to pipeline concerns, patent cliff dynamics, or broader sector headwinds in large-cap biopharma. The stock's proximity to its 52-week high of $302.93 means there is limited technical cushion above current levels, while the gap back to the $260 strike gives the puts room to move into the money if sentiment shifts.
ABBV Unusual Options Activity
Two unusual put contracts were flagged in Wednesday's session, both concentrated at the same strike and expiration:
- Contract 1: PUT | Strike: $260 | Expiry: December 17, 2027 | Size: 1,200 | Open Interest Ratio: 8,000% | Status: Out of the Money | Premium: $2,293,200
- Contract 2: PUT | Strike: $260 | Expiry: December 17, 2027 | Size: 300 | Open Interest Ratio: 2,000% | Status: Out of the Money | Premium: $573,300
No call-side unusual activity was flagged in today's session. The total unusual premium across both contracts came to $2,866,500, entirely on the put side, with zero unusual call contracts reported.
ABBV Seasonality
Mid-to-late November historically marks a transitional period for large-cap healthcare names as institutional investors rebalance portfolios ahead of year-end. Options positioning with December 2027 expirations placed in November 2026 may also reflect a strategy designed to straddle the company's next several earnings cycles and any anticipated pipeline or regulatory catalysts through the coming year.
ABBV Relative Performance
ABBV is down 1.99% on Wednesday, underperforming on a session basis. With the stock sitting at $287.02 against a 52-week range of $191.00 to $302.93, it remains within roughly 5% of its annual high, indicating that despite today's pullback, the longer-term trend has strongly favored bulls. However, the fresh put activity suggests at least one market participant believes the stock's proximity to its 52-week peak may limit near-term upside while increasing the risk of a larger reversal over the next year.
More on ABBV
- AbbVie Stock Creeps Toward 52-Week High as Shares Trade at $296.98
- AbbVie Stock Inches Toward 52-Week High as Shares Trade at $297.45
- AbbVie Stock Holds Near 52-Week High of $298.74 as Shares Hover at $294.68
- AbbVie Stock Hovers Just Below 52-Week High of $298.74 as Shares Slip 0.05%
- AbbVie Tops Q3 2026 Estimates on EPS and Revenue, Shares Push to New 52-Week High
Latest Market News
- Palo Alto Networks Drops 7.94% Despite 20 Analyst Confirmations and $432 Average Price Target
- Meta Platforms Drops Nearly 6% as Shares Slide Toward 52-Week Low Territory
- Oracle Stock Craters 6.4%, Breaking Below Its 52-Week Low to $103.44
- QUALCOMM Shares Plunge 7.41% to $150.01, Nearing 52-Week Lows
- CrowdStrike Shares Crater 15% on Friday, Erasing Months of Gains in a Single Session
- Snowflake Shares Tumble 5.13% as Stock Retreats Sharply from Recent Highs